BRPI0923663A2 - agente profilático/terapêutico para câncer independente de androgênio, e, uso de um derivado de metastina - Google Patents

agente profilático/terapêutico para câncer independente de androgênio, e, uso de um derivado de metastina

Info

Publication number
BRPI0923663A2
BRPI0923663A2 BRPI0923663A BRPI0923663A BRPI0923663A2 BR PI0923663 A2 BRPI0923663 A2 BR PI0923663A2 BR PI0923663 A BRPI0923663 A BR PI0923663A BR PI0923663 A BRPI0923663 A BR PI0923663A BR PI0923663 A2 BRPI0923663 A2 BR PI0923663A2
Authority
BR
Brazil
Prior art keywords
prophylactic
therapeutic agent
androgen independent
independent cancer
metastine derivative
Prior art date
Application number
BRPI0923663A
Other languages
English (en)
Portuguese (pt)
Inventor
Hisanori Matsui
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42025816&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0923663(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0923663A2 publication Critical patent/BRPI0923663A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0923663A 2008-12-29 2009-12-28 agente profilático/terapêutico para câncer independente de androgênio, e, uso de um derivado de metastina BRPI0923663A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20388708P 2008-12-29 2008-12-29
PCT/JP2009/071919 WO2010076896A1 (en) 2008-12-29 2009-12-28 Prophylactic/therapeutic agent for cancer

Publications (1)

Publication Number Publication Date
BRPI0923663A2 true BRPI0923663A2 (pt) 2016-01-19

Family

ID=42025816

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923663A BRPI0923663A2 (pt) 2008-12-29 2009-12-28 agente profilático/terapêutico para câncer independente de androgênio, e, uso de um derivado de metastina

Country Status (26)

Country Link
US (1) US20110312898A1 (enExample)
EP (1) EP2379053A1 (enExample)
JP (1) JP2012513982A (enExample)
KR (1) KR20110111420A (enExample)
CN (1) CN102333520B (enExample)
AR (1) AR074918A1 (enExample)
AU (1) AU2009334235A1 (enExample)
BR (1) BRPI0923663A2 (enExample)
CA (1) CA2748517A1 (enExample)
CL (1) CL2011001519A1 (enExample)
CO (1) CO6382105A2 (enExample)
CR (1) CR20110374A (enExample)
DO (1) DOP2011000163A (enExample)
EA (1) EA019738B1 (enExample)
EC (1) ECSP11011166A (enExample)
GE (1) GEP20146001B (enExample)
IL (1) IL212913A0 (enExample)
MA (1) MA32935B1 (enExample)
MX (1) MX2011006170A (enExample)
NZ (1) NZ593381A (enExample)
PE (1) PE20110939A1 (enExample)
TN (1) TN2011000250A1 (enExample)
TW (1) TW201029660A (enExample)
UY (1) UY32367A (enExample)
WO (1) WO2010076896A1 (enExample)
ZA (1) ZA201103627B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592379B2 (en) * 2008-04-30 2013-11-26 Kyoto University Metastin derivative and use thereof
MA33910B1 (fr) * 2009-12-22 2013-01-02 Takeda Pharmaceutcal Company Ltd Formulation à libération prolongée
EA021663B1 (ru) * 2010-06-25 2015-08-31 Такеда Фармасьютикал Компани Лимитед Композиция с замедленным высвобождением, способ ее получения и способ лечения рака
JP6253146B2 (ja) * 2014-02-04 2017-12-27 国立大学法人山口大学 新規なペプチド誘導体及びこれを含有する医薬
EA201700154A1 (ru) * 2014-10-20 2017-08-31 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Фармацевтический состав лечебно-профилактического действия и способ его приготовления
IL311335A (en) 2016-09-30 2024-05-01 Sumitomo Pharma Switzerland Gmbh Methods for treating female infertility
WO2024206577A1 (en) * 2023-03-28 2024-10-03 Radionetics Oncology, Inc. Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050090420A (ko) 2002-12-26 2005-09-13 다케다 야쿠힌 고교 가부시키가이샤 메타스틴 유도체 및 이의 용도
US6800611B2 (en) * 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
WO2006001499A2 (en) * 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
CN1972959A (zh) * 2004-06-25 2007-05-30 武田药品工业株式会社 转移素衍生物及其用途
TWI386417B (zh) * 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途

Also Published As

Publication number Publication date
JP2012513982A (ja) 2012-06-21
US20110312898A1 (en) 2011-12-22
ECSP11011166A (es) 2011-07-29
ZA201103627B (en) 2012-09-26
UY32367A (es) 2010-07-30
MA32935B1 (fr) 2012-01-02
CL2011001519A1 (es) 2012-03-16
DOP2011000163A (es) 2011-07-31
EA019738B1 (ru) 2014-05-30
CN102333520A (zh) 2012-01-25
TW201029660A (en) 2010-08-16
PE20110939A1 (es) 2012-01-19
NZ593381A (en) 2013-01-25
CO6382105A2 (es) 2012-02-15
CA2748517A1 (en) 2010-07-08
WO2010076896A1 (en) 2010-07-08
TN2011000250A1 (en) 2012-12-17
IL212913A0 (en) 2011-07-31
CN102333520B (zh) 2013-11-06
AR074918A1 (es) 2011-02-23
CR20110374A (es) 2011-09-19
EA201100882A1 (ru) 2011-12-30
AU2009334235A1 (en) 2010-07-08
MX2011006170A (es) 2011-06-27
GEP20146001B (en) 2014-01-10
KR20110111420A (ko) 2011-10-11
EP2379053A1 (en) 2011-10-26

Similar Documents

Publication Publication Date Title
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BRPI1010937A2 (pt) composto, uso de um composto, e, método para tratar câncer
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0908100A2 (pt) produto combinação, uso de um composto, e, método de tratar câncer
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
IL220129A (en) History of benzamide, preparations containing them and their use in the treatment of cancer
BR112013023175A2 (pt) composto, inibidor, medicamento, agente anticâncer, composição farmacêutica, método para o tratamento de câncer, e, uso de um composto
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0910760A2 (pt) método para remineralizar tecido, agente remineralizador, e, kit
BRPI0914069A2 (pt) composição de vacina para uso contra o influenza
BRPI0923663A2 (pt) agente profilático/terapêutico para câncer independente de androgênio, e, uso de um derivado de metastina
EP2127671A4 (en) THERAPEUTIC CANCER
BRPI0921303A2 (pt) agente redutor de rugas, composto, e, preparação externa para a pele.
BR112012003372A2 (pt) vitamina d3 e análogos da mesma para o tratamento de alopecia.
BRPI0719523A2 (pt) Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
BR112013014522A2 (pt) anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
BRPI0920862A2 (pt) composição, método para fabricação da mesma, e uso da mesma
BR112013014189A8 (pt) composição farmacêutica, uso de um agente de potencialização e uso de uma composição
BR112012008470A2 (pt) composição externa para pele para a prevenção e tratamento da vaginose, uso e método para preparar a mesma
BRPI0917026A2 (pt) uso de sucralose como agente granulador
BRPI0815726A2 (pt) terapia de combinação para câncer pancreático utilizando um peptídeo antigênico e agente quimioterápico
BRPI0910912A2 (pt) Composto, prodroga, ativador de glicocinase, agente farmacêutico, e, uso do composto
BR112013002441A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer
BRPI1007334A2 (pt) composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2370 DE 07-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.